ELIANA Phase 2 trial

January 18, 2018January 18, 2018

FDA Promises Rapid Review of Kymriah for Diffuse Large B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) will prioritize the regulatory review of Novartis’ application to use Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large ... Read more

November 8, 2017

Novartis Files for Approval of Kymriah for Two Blood Cancers in the EU

News

Novartis continues the process of making Kymriah (tisagenlecleucel) commercially available outside the U.S., now by applying with the European Medicines Agency (EMA) to approve the treatment for two types of ... Read more